Studies have shown that LCNEC can be further divided into SCLC-like with TP53/RB1 inactivation and NSCLC-like with retained TP53/RB1 functions, with different chemotherapy treatment results (Derks et al., 2018). Here, TP53 is linked to large cell neuroendocrine carcinoma.